Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (14474)	2/9/1998 8:57:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Goldman Sachs took Novartis (NVTSY) off its Global Prioity list and said the merger of GLX/SBH will cause R&D spending to expand. CNBC just ran a short story on the downgrade (to market perform?).

To: celeryroot.com who wrote (14474)	2/9/1998 11:02:00 AM
From: Henry Niman	Respond to of 32384

Here's a brief Reuter's report on the Novartis downgrade: RESEARCH ALERT - Novartis downgraded Reuters Story - February 09, 1998 09:37 %DRU %CH %US %RCH %HOT NOVZn.S V%REUTER P%RTR NEW YORK, Feb 9 (Reuters) - Goldman Sachs said on Monday it removed shares of Novartis AG from the firm's global list and European recommended list and now rates the stock a market perform. -- Further details not immediately available. -- Stock off 60 Swiss francs at 2527.